Full Press Release Details
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in the following upcoming investor conferences in September:
Citi's 2026 Biopharma Back to School ConferenceFormat: 1x1 meetingsDate: Wednesday, September 9, 2026
Cantor Global Healthcare ConferenceFormat: Fireside chatDate: Thursday, September 10, 2026Time: 8:00 a.m. Eastern Time
H.C. Wainwright 28thAnnual Global Investment ConferenceFormat: PresentationDate: Monday, September 14, 2026Time: 12:00 p.m. Eastern Time
Morgan Stanley 24thAnnual Global Healthcare ConferenceFormat: 1x1 meetingsDate: Tuesday, September 15, 2026
A live webcast of the presentations can be accessed under “Events & Presentations” in the Investor Relations section of the Company’s website athttps://investor.inva.com/presentations-events. An archived replay of the webcasts will be available following each presentation date.
About Innoviva
Innoviva is a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets. Innoviva’s royalty portfolio includes respiratory assets partnered with Glaxo Group Limited (“GSK”). Innoviva is entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. Innoviva’s critical care and infectious disease assets under the IST platform include GIAPREZA® (angiotensin II) for increasing blood pressure in adults with septic or other distributive shock, XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use for the treatment of adults with hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible strains ofAcinetobacter baumannii-calcoaceticus, XERAVA® (eravacycline) for the treatment of complicated intra-abdominal infections in adults, ZEVTERA (ceftobiprole), an advanced-generation cephalosporin antibiotic licensed from Basilea Pharmaceutica International Ltd, Allschwil, and NUZOLVENCE® (zoliflodacin), approved by the FDA for the oral treatment of uncomplicated urogenital gonorrhea in adults and pediatric patients 12 years of age and older weighing at least 35 kg. For more information about Innoviva, go towww.inva.com. For information about Innoviva Specialty Therapeutics, go towww.innovivaspecialtytherapeutics.com.
ANORO®, RELVAR® and BREO® are trademarks of the GSK group of companies. ZEVTERA is a trademark of Basilea Pharmaceutica Ltd, Allschwil.